Burch Patrick, Holm Soren
Centre for Primary Care, The University of Manchester, Manchester, UK
Centre for Social Ethics and Policy, School of Law, University of Manchester, Manchester, UK.
J Med Ethics. 2021 Nov;47(11):719-721. doi: 10.1136/medethics-2020-106573. Epub 2020 Nov 4.
Pre-diabetes is a risk factor for the development of diabetes, not a disease in its own right. The prevalence increases with age and reaches nearly 50% of those aged over 75 years in the USA. While lifestyle modification and treatment are likely to benefit those with many years of life ahead of them, they are unlikely to benefit patients with a limited life expectancy. Despite this, some very elderly patients in the UK and elsewhere are being labelled as pre-diabetic. While ideal practice would be to carefully consider the impact of any potentially abnormal blood test before it is taken, this is not always possible in routine practice. In this paper, we discuss a pragmatic, ethical approach for clinicians managing pre-diabetic blood tests in very elderly patients. We argue that a 'see-saw' model of paternalism should be used in deciding which patients to inform that they can be labelled as pre-diabetic. Those patients that may benefit from the label should be informed, and those that will not, should not. Where the benefits/drawbacks are unclear, the result and its potential significance should be discussed in depth with the individual patient. We do not advocate withholding information from any patient. Instead we suggest clinicians use individual patient circumstances to contextualise the relevance of pre-diabetes to the patient and consider the benefits and drawbacks before informing them. This approach has the potential to be used for other pre-conditions and risk factors in addition to pre-diabetes.
糖尿病前期是糖尿病发展的一个风险因素,其本身并非一种疾病。患病率随年龄增长而上升,在美国75岁以上人群中患病率接近50%。虽然生活方式的改变和治疗可能会使那些还有多年寿命的人受益,但对于预期寿命有限的患者来说可能并无益处。尽管如此,英国和其他地方的一些高龄患者仍被诊断为糖尿病前期。虽然理想的做法是在进行任何可能异常的血液检测之前仔细考虑其影响,但在常规临床实践中这并不总是可行的。在本文中,我们讨论了一种务实的、符合伦理的方法,供临床医生管理高龄患者的糖尿病前期血液检测。我们认为,在决定告知哪些患者他们可被诊断为糖尿病前期时,应采用一种家长式的“跷跷板”模式。那些可能从该诊断中受益的患者应被告知,而那些不会受益的患者则不应被告知。在利弊不明的情况下,应与患者本人深入讨论检测结果及其潜在意义。我们不主张对任何患者隐瞒信息。相反,我们建议临床医生根据患者的具体情况来确定糖尿病前期对患者的相关性,并在告知患者之前考虑其利弊。除糖尿病前期外,这种方法还可能用于其他前期病症和风险因素。